The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.